Baxalta

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts

Retrieved on: 
星期四, 四月 25, 2024
Genetics, CMO, Doctor of Philosophy, Boston, Development, Novartis, Pfizer, Operating partner, Functional genomics, CSO, Genome, Associate, Drug discovery, SAB, AbbVie, Baxalta, EVP, GSK plc, Bristol Myers Squibb, GSK, Baylor College of Medicine, University, Harvard Medical School, Therapy, Biotechnology, Inflammation, Hospital, NIH, Michigan State University, Respiratory Medicine, Imperial College London, IPO, Rockefeller University, Spatial, MPH, Genomics, Atlas Venture, Merck Serono, Genentech, University of Birmingham, Senior, Society, Acquisition, Discovery, Sanofi, Baylor University

New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.

Key Points: 
  • New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.
  • The SAB is chaired by Prof. Jim Hughes, Scientific Founder and Non-Executive Director of Nucleome Therapeutics.
  • Dr Russell Greig, Non-Executive Chair of the Nucleome’s Board, said: “We are delighted to have appointed such esteemed experts to the Nucleome team.
  • Steve’s multifaceted background, spanning academia, industry and leadership roles, positions him as a key contributor to Nucleome’s Scientific Advisory Board.

Pathway to Cures Announces First Entrepreneur in Residence

Retrieved on: 
星期一, 三月 11, 2024
Other Philanthropy, Biotechnology, Pharmaceutical, Health, Philanthropy, Fund Raising, Foundation, Other Health, Disease, Coagulopathy, Sickle cell disease, Heredity, Spark Therapeutics, Rush University Medical Center, Entrepreneur in residence, Knowledge, Mortality, Baxalta, EIR, Doctor of Philosophy, MD, MBA, Therapy, Anemia, Blood

Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D.

Key Points: 
  • Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D.
  • Dr. Valentino most recently served as President and CEO of the National Bleeding Disorders Foundation (NBDF) and was instrumental in bringing Pathway to Cures into reality.
  • Pathway to Cures is the venture philanthropy fund of the NBDF focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • “My role as Entrepreneur in Residence for Pathway to Cures will be to provide guidance into the consideration and support of new opportunities for catalyzing transformative therapies and cures.

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Retrieved on: 
星期一, 三月 11, 2024
Therapy, Breast cancer, SAN, Pharmacology, ARIAD Pharmaceuticals, Biotechnology, Baxalta, Bone marrow, Drug development, Prostate, Acute leukemia, Acting, Stomach, Sanofi, Oxaliplatin, Astellas Pharma, Patient, Oncology, Qasr El Eyni Hospital, Stromal cell, Pancreatic cancer, IND, Head, Colorectal cancer, Cancer, Prostate cancer, Medical imaging

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.
  • “Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen.
  • “We will benefit immensely from Deyaa’s broad and deep experience in oncology drug development, including his experiences in both pancreatic and prostate cancers.”
    “I am excited to join FibroGen and lead the clinical development organization at this important time for our company,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics Inc. where he led the transition of two novel cell therapy programs into clinical development.

Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer

Retrieved on: 
星期一, 九月 11, 2023
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Baxalta, CRISPR, Employment, Momenta, Telomerase, Finance, History, Editas Medicine, Baxter International, Genzyme, Imetelstat, Bentley University, Retirement, Corporation, Acquisition, Geron Corporation, Risk, Syndrome, CFO, Johnson & Johnson, Commercial, Treasurer, Genome, Management, Sanofi, Accounting

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023.
  • Ms. Robertson's appointment follows the retirement of Olivia Bloom, Geron's incumbent CFO, also effective September 25, 2023.
  • Olivia’s strategic vision, financial prowess and inspiring dedication have been foundational in making Geron what we are today,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer.
  • “In the same breath, I am also thrilled to welcome Michelle Robertson to the Geron executive management team at this important moment in our history.

Vaccentis Appoints Dr. Ingrid Rauter as Chief Medical Officer and Head of Research & Development

Retrieved on: 
星期三, 五月 3, 2023
Baxalta, Culture, Progression-free survival, Takeda, Science Fund of the Republic of Serbia, RCC, Head, Amgen, Erwin, CMO, Nephrectomy, Doctor of Philosophy, Harvard Medical School, Hospital, Patient, Risk, Immune system, Recurrence, PT3, Vaccine, Pharmaceutical industry

Zurich, Switzerland, May 3, 2023 - Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines, today announced the appointment of the experienced life science executive Ingrid Rauter as Head of R&D and Chief Medical Officer.

Key Points: 
  • Zurich, Switzerland, May 3, 2023 - Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines, today announced the appointment of the experienced life science executive Ingrid Rauter as Head of R&D and Chief Medical Officer.
  • Ingrid Rauter, PhD, has successfully led global research and clinical development programs for pipeline and marketed products for over ten years.
  • “I am delighted to welcome Dr Ingrid Rauter to Vaccentis as Chief Medical Officer and Head of R&D,” said Martin Munte, Chief Executive Officer of Vaccentis.
  • “Ingrid brings a wealth of experience in biopharmaceutical industry R&D and medical affairs to Vaccentis.

CRB Board of Directors adds CEO title to President Ryan Schroeder; Company announces Sam Kitchell as new Chief Operating Officer

Retrieved on: 
星期二, 三月 28, 2023
Vaccine, Heart, Baxalta, Food, Swiss Research Centre for Rationalization in Building and Civil Engineering CRB, Engineering, EBO, COVID-19, GCP, Kitchell, Research, Baxter International, Architecture, Growth, News, Management, Takeda, CRB

KANSAS CITY, Mo., March 28, 2023 /PRNewswire/ -- CRB, a leading global provider of sustainable engineering, architecture, construction, and consulting solutions to the biopharmaceutical and food and beverage industries, today announced the Board of Directors has named President Ryan Schroeder as Chief Executive Officer. Schroeder succeeds CEO and CRB co-founder Jeff Biskup, who will remain on the Board of Directors and lead the board as Executive Chairman.

Key Points: 
  • Schroeder succeeds CEO and CRB co-founder Jeff Biskup, who will remain on the Board of Directors and lead the board as Executive Chairman.
  • CRB announced Ryan Schroeder as its new Chief Executive Officer, and Sam Kitchell as its new Chief Operating Officer.
  • Additionally, the company announced the formation of CRB Operations, a group uniting the company's Regional Operations and Technical Operations teams into a single structure and led by new Chief Operating Officer Sam Kitchell.
  • He was named President in 2017 and has led the company through unprecedented growth including its first $1 billion-plus revenue years in 2021 and 2022.

BIOCARE NAMES TWO HEALTHCARE INDUSTRY VETERANS TO LEADERSHIP POSITIONS

Retrieved on: 
星期二, 二月 7, 2023
Linda, Wuhan Institute of Biological Products, Operation, McKesson Corporation, Collins, Baxalta, Nobel Biocare, CRM, Marketing, Biomatrix systems theory, Management, Health care, Kissling

TEMPE, Ariz., Feb. 7, 2023 /PRNewswire/ -- BioCare, Inc., specializing in delivering specialty and therapeutic biological products since 1982, has named two healthcare industry veterans to their leadership team. Healthcare sales executive Mike Collins was named Vice President of Sales for BioCareSD, the company's specialty distribution business. Operations executive Kevin Kissling was named Vice President & General Manager 3PL Services, leading LogiCare3PL, BioCare's third-party logistics offering.

Key Points: 
  • Healthcare Sales Executive Mike Collins to Lead Sales Team; Senior Operations Executive Kevin Kissling to Head LogiCare3PL
    TEMPE, Ariz., Feb. 7, 2023 /PRNewswire/ -- BioCare, Inc., specializing in delivering specialty and therapeutic biological products since 1982, has named two healthcare industry veterans to their leadership team.
  • Healthcare sales executive Mike Collins was named Vice President of Sales for BioCareSD, the company's specialty distribution business.
  • "We are thrilled to bring two industry veterans with deep experience in their specialties to the BioCare team," said CEO Linda Matthews.
  • Throughout his 25-year career in the healthcare industry, Collins has experience working with pharmaceutical, biopharmaceutical, and specialty pharmacy organizations.

Pheast Appoints Jacopo Leonardi as Chief Executive Officer

Retrieved on: 
星期四, 一月 5, 2023
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Carbon, Immunology, Baxalta, Cancer, Translation, Horizon Therapeutics, Eli Lilly, CD24, Therapy, Research, Series, R, Johnson & Johnson, Patient, Macrophage, Aggression, Baxter International, Shire, Marketing, Pharmaceutical industry, Management

Pheast Therapeutics , a private biotechnology company developing novel innate immune checkpoint inhibitors to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced the appointment of Jacopo Leonardi as Chief Executive Officer.

Key Points: 
  • Pheast Therapeutics , a private biotechnology company developing novel innate immune checkpoint inhibitors to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced the appointment of Jacopo Leonardi as Chief Executive Officer.
  • Amira Barkal, M.D., Ph.D., principal founder and founding CEO of Pheast Therapeutics, will now serve as Chief Development Officer.
  • At Baxalta, Mr. Leonardi was Executive Vice President and President of Immunology and was a member of the Executive Leadership Team that spun Baxalta out of Baxter Healthcare, which was subsequently acquired by Shire PLC.
  • Pheast completed its Series A financing of $76M in April 2022, led by high profile investors, Catalio Capital Management and Arch Venture Partners.

SK pharmteco appoints Joerg Ahlgrimm as CEO

Retrieved on: 
星期二, 十一月 1, 2022
API, Growth, Plasma, Board of directors, CEO, Telecommunication, CMOS, Leadership, Semiconductor, Center, CGMP, Board, Industry, CGT, Plant, CDMO, Substance-related disorder, Cell, View, Collection, Baxter International, Gene, Technology, 2009 Davis Cup, EV, SK Group, Director, Multimedia, Baxalta, Isolde Ahlgrimm, CBM, Management, Renewable energy, Fine chemical

"I am delighted to join forces with the SK pharmteco team to drive further growth of the company," said Ahlgrimm.

Key Points: 
  • "I am delighted to join forces with the SK pharmteco team to drive further growth of the company," said Ahlgrimm.
  • His leadership was retained by SK Inc. when it acquired AMPAC Fine Chemicals in 2018 and established SK pharmteco in 2019.
  • Headquartered in Sacramento, California, SK pharmteco is a global CDMO and a subsidiary of SK Inc., the strategic investment company for SK Group, South Korea's second-largest conglomerate.
  • SK pharmteco is the single customer-facing team comprised of SK biotek Ireland, AMPAC Fine Chemicals, SK biotek Korea, Yposkesi and most recently The Center for Breakthrough Medicines.

SK pharmteco appoints Joerg Ahlgrimm as CEO to spearhead the next phase of company growth and innovation

Retrieved on: 
星期二, 十一月 1, 2022
API, Growth, Plasma, Board of directors, CEO, CMOS, Leadership, Center, CGMP, Board, Industry, COVID-19, CGT, Plant, CDMO, KRW, Substance-related disorder, Cell, Collection, Baxter International, Gene, Technology, 2009 Davis Cup, SK Group, Director, Baxalta, Isolde Ahlgrimm, CBM, Diabetes, Management, Fine chemical, Synthetic rubber

FRANKFURT, Germany, Nov. 1, 2022 /PRNewswire/ -- SK pharmteco, a global contract development and manufacturing organization (CDMO) serving the pharmaceutical industry, today announced that Joerg Ahlgrimm will be appointed as the Chief Executive Officer. Ahlgrimm will assume the global leadership of the company and spearhead its next phase of innovation and global growth.

Key Points: 
  • Ahlgrimm will assume the global leadership of the company and spearhead its next phase of innovation and global growth.
  • "I am delighted to join forces with the SK pharmteco team to drive further growth of the company," said Ahlgrimm.
  • I strongly believe Joerg will successfully lead SK pharmteco to its next phase of growth," said Dr. Malik.
  • SK pharmteco is a portfolio company of SK Inc. (South Korea) and serves as a strategic part of SK's growing pharmaceutical sector.